Affiliation:
1. Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India
Abstract
Background:
The high mobility group box 1 (hmgb1) is one of the frequently over-expressed genes
whose aberrant expression is reported in a number of human cancers. Various strategies are underway to inhibit
hmgb1 expression in cancer cells having considerable therapeutic value.
Objective:
The present work involves selective transcriptional inhibition of the hmgb1 gene using selective DNA
triplex structure-based gene technology. Here, the promoter region of the hmgb1 gene at position (-183 to -165) from
the transcription start site as a target was selected using bioinformatic tools.
Methods:
The DNA triplex formation by the DNA of the target gene and TFO was confirmed using UV absorption
spectroscopy, Circular Dichroism, and Isothermal Calorimetry.
Results:
Treatment of HepG2 cell with specific Triplex-forming Oligonucleotide significantly downregulated
HMGB1 expression level at mRNA and protein levels by 50%, while the classical anticancer drugs, actinomycin/
adriamycin as positive controls showed 65% and the combination of TFO and drug decreased by 70%. The
anti-proliferative effects of TFO correlated well with the fact of accumulation of cells in the Go phase and apoptotic
cell death. Further, the binding of anti-cancer drugs to hmgb1 is stronger in DNA triplex state as compared
to hmgb1 alone, suggesting the combination therapy as a better option.
Conclusion:
Therefore, the ability of hmgb1 targeted triplex-forming oligonucleotide in combination with triplex
selective anticancer drug holds promise in the treatment of malignancies associated with hmgb1 overexpression.
The result obtained may open up new vistas to provide a basis for the rational drug design and searching
for high-affinity ligands with a high triplex selectivity.
Publisher
Bentham Science Publishers Ltd.
Subject
Cancer Research,Pharmacology,Molecular Medicine
Reference48 articles.
1. Lohani N.; Rajeswari M.R.; Dichotomous life of DNA binding high mobility group box1 protein in human health and disease. Curr Protein Pept Sci 2016,17(8),762-775
2. Tang D.; Kang R.; Zeh H.J.; Lotze M.T.; High-mobility group box 1 and cancer. Biochim Biophys Acta 2010,1799(1-2),131-140
3. Ishiguro H.; Nakaigawa N.; Miyoshi Y.; Fujinami K.; Kubota Y.; Uemura H.; Receptor for Advanced Glycation End products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 2005,64(1),92-100
4. Liu Z.; Xu Y.; Long J.; Guo K.; Ge C.; Du R.; microRNA-218 suppresses the proliferation, invasion and promotes apoptosis of pancreatic cancer cells by targeting HMGB1. Chin J Cancer Res 2015,27(3),247-257
5. Lin L.; Zhong K.; Sun Z.; Wu G.; Ding G.; Receptor for Advanced Glycation End products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma. J Cancer Res Clin Oncol 2012,138(1),11-22
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献